NxStage(R) Reports Third Quarter 2009 Financial Results and Raises Revenue Guidance for F...(2009 2008 ...),Health

Date:11/5/2009

2009 2008 ---- ---- Cash flows from operating activities: Net loss $(34,790) $(41,448) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 15,367 14,073 Stock-based compensation 6,392 4,456 Change in fair value of financial instruments - (251) Other 1,977 660 Changes in operating assets and liabilities: Accounts receivable 337 (1,248) Inventory (3,707) (24,511) Prepaid expenses and other current assets 682 1,073 Accounts payable 25 (4,713) Accrued expenses and other liabilities 1,455 (3,375) Deferred revenue (653) 8,331 ---- ----- Net cash used in operating activities $(12,915) $(46,953) ======== ======== NxStage Medical, Inc. Revenues by Segment (in thousands) Three Months Ended Nine Months Ended September 30, September 30, ------------- ------------- 2009 2008 2009 2008 ---- ---- ---- ---- System One segment Home $16,356 $12,412 $45,914 $34,807 Critical Care 5,672 4,401 15,381 13,107 ----- ----- -----
'/>"/>

SOURCE NxStage Medical, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. NxStage(R) to Recognize Several Key Milestones at American Society of Nephrologys Renal Week 2007
2. Boston Business Journal Names NxStage(R) Medical Third Fastest Growing Company in Massachusetts
3. NxStage(R) to Report Third Quarter 2009 Financial Results
4. NxStage(R) Reports Significant Interim FREEDOM Study Results
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress